





Supplementary Figure 1. Serum IgM reactivity of diagnostic samples with OspC and OspC-derived peptides. DI serum samples (diluted 1:100) were subject to MIA using microspheres coated with recombinant dimeric OspC types A, B and K and OspC-peptides as described in Table 1. Panels are labeled by corresponding residue numbers for each OspC type. MFI values were log₁₀ transformed and compared to the control sample set. Significance was determined by the Mann-Whitney U-test and Student t-test depending on data distribution (*, $P < 0.05$).



Supplementary Figure 2. Hierarchical clustering of rOspC and OspC-derived reactivity in diagnostic and PTL D serum by ELISA. PTL D serum samples (diluted 1:50; n=18) were subject to ELISA using microtiter plates coated with recombinant dimeric OspCA and a subset of the OspC-peptides described in Table 1. Heatmaps were generated using PTL D serum sample log₁₀ transformed OD results. Rows represent individual samples and columns represent the panel of antigens. The columns were subjected to hierarchical clustering by correlation and the rows were clustered by Euclidean distance to better visualize patterns in reactivity profiles.

Supplementary Table 1. IgG reactivity (>3SD) to OspC_{A/B/K} and OspC peptides in diagnostic and PTL D serum samples

OspC / peptide	Diagnostic		PTLD	
	n = (%) ^a	Fold increase (SD) ^b	n = (%) ^a	Fold increase (SD) ^b
OspC _A	240 (34.5)	3.7 (3.2)	43 (27.2)	7.0 (9.0)
OspC _B	388 (55.7)	5.0 (5.4)	6 (3.8)	3.6 (1.3)
OspC _K	243 (34.9)	6.1 (6.4)	38 (24.1)	3.9 (3.7)
9-33 _{ABK}	7 (1.0)	1.8 (1.2)	1 (0.6)	1.2 (N/A)
40-55 _{AB}	45 (6.5)	2.3 (2.0)	7 (4.4)	2.3 (1.1)
40-55 _K	16 (2.3)	1.9 (1.0)	5 (3.2)	1.8 (0.6)
71-86 _A	92 (13.2)	1.7 (1.1)	5 (3.2)	1.5 (0.5)
132-146 _A	46 (6.6)	2.5 (2.2)	9 (5.7)	2.4 (1.3)
132-146 _B	118 (17.0)	2.1 (1.8)	21 (13.3)	3.2 (2.9)
133-147 _K	75 (10.8)	2.6 (3.3)	15 (9.5)	2.9 (2.1)
155-169 _A	75 (10.8)	2.6 (3.3)	10 (6.3)	2.8 (2.4)
177-186 _A	82 (11.8)	1.9 (1.0)	28 (17.7)	2.7 (2.7)
178-187 _K	164 (23.6)	1.8 (1.0)	30 (19.0)	3.1 (3.7)
178-187 _B	24 (3.4)	1.5 (0.4)	25 (15.8)	2.7 (2.7)
183-190 _{AB} ^c	110 (15.8)	2.1 (1.4)	22 (13.9)	3.7 (4.5)
193-210 _A (C10)	272 (39.1)	5.4 (6.8)	36 (22.8)	3.8 (4.3)
VlsE C6-17	537 (77.2)	9.2 (5.3)	78 (49.4)	7.8 (8.1)

^a, The number of samples (n =) and percent reactivity (“%”) to each antigen in the diagnostic (n=696) and PTL D (n=158) sample sets were calculated using a cutoff of >3SD above the mean of controls samples; ^b, The fold increase of positive sample antibody reactivity over controls such that an index value of 1 is 3SD above the control mean, while 3.7 corresponds to ~11SD greater than the mean control. ^c, OspC_B residues 184-191

Supplementary Table 2. Serum IgM reactivity greater than 3SD and 6SD to OspC_{A/B/K} and OspC peptides in diagnostic serum samples

	3SD	6SD
OspC / peptide	n = (%) ^a	n = (%) ^a
OspC _A	398 (57.2)	306 (44.0)
OspC _B	309 (44.4)	234 (33.6)
OspC _K	219 (31.5)	172 (24.7)
9-33 _{ABK}	22 (3.2)	5 (0.7)
40-55 _{AB}	25 (3.6)	1 (0.1)
40-55 _K	18 (2.6)	5 (0.7)
71-86 _A	24 (3.4)	4 (0.6)
132-146 _A	32 (4.6)	9 (1.3)
132-146 _B	32 (4.6)	4 (0.6)
133-147 _K	38 (5.5)	6 (0.9)
155-169 _A	57 (8.2)	19 (2.7)
177-186 _A	27 (3.9)	1 (0.1)
178-187 _K	170 (24.4)	61 (8.8)
178-187 _B	100 (14.4)	40 (5.7)
183-190 _{AB} ^b	32 (4.6)	5 (0.7)
193-210 _A (C10)	57 (8.2)	14 (2.0)

^a, The number of samples (n=) and percent reactivity (“%”) to each antigen in the diagnostic (n=696) sample set were calculated using cutoffs of >3SD and >6SD above the mean of controls samples; ^b, Residues 184-191 in Type B.